TY  - JOUR
A1  - Wiegering, Verena
A1  - Andres, Oliver
A1  - Schlegel, Paul G.
A1  - Deinlein, Frank
A1  - Eyrich, Matthias
A1  - Sturm, Alexander
T1  - Hyperfibrinolysis and acquired factor XIII deficiency in newly diagnosed pediatric malignancies
JF  - Haematologica
N2  - No abstract available
KW  - factor XIII deficiency
KW  - leukemia
KW  - tumor
KW  - perioperative bleeding
KW  - coagulopathy
KW  - hyperfibrinolysis
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130569
VL  - 98
IS  - 8
ER  - 
TY  - JOUR
A1  - Wiegering, Verena
A1  - Schmid, Sophie
A1  - Andres, Oliver
A1  - Wirth, Clemens
A1  - Wiegering, Armin
A1  - Meyer, Thomas
A1  - Winkler, Beate
A1  - Schlegel, Paul G.
A1  - Eyrich, Matthias
T1  - Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience
N2  - Background

Reliable central venous access (CVC) is essential for hematology–oncology patients since frequent puncture of peripheral veins—e.g., for chemotherapy, antibiotic administration, repeated blood sampling, and monitoring—can cause unacceptable pain and psychological trauma, as well as severe side effects in cases of extravasation of chemotherapy drugs. However, CVC lines still carry major risk factors, including thrombosis, infection (e.g., entry site, tunnel, and luminal infections), and catheter dislocation, leakage, or breakage.

Methods

Here we performed a retrospective database analysis to determine the incidence of CVC-associated thrombosis in a single-center cohort of 448 pediatric oncologic patients, and to analyze whether any subgroup of patients was at increased risk and thus might benefit from prophylactic anticoagulation.

Results

Of the 448 patients, 269 consecutive patients received a CVC, and 55 of these 269 patients (20%) also had a thrombosis. Of these 55 patients, 43 had at least one CVC-associated thrombosis (total number of CVC-associated thrombosis: n = 52). Among all patients, the median duration of CVC exposure was 464 days. Regarding exposure time, no significant difference was found between patients with and without CVC-associated thrombosis. Subclavia catheters and advanced tumor stages seem to be the main risk factors for the development of CVC-associated thrombosis, whereas pharmacologic prophylaxis did not seem to have a relevant impact on the rate of thrombosis.

Conclusions

We conclude that pediatric surgeons and oncologists should pay close attention to ensuring optimal and accurate CVC placement, as this appears the most effective tool to minimize CVC-associated complications.
KW  - Pediatric malignancy
KW  - Central venous access
KW  - Port
KW  - Hickman catheter
KW  - Thrombosis
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-110476
ER  - 
TY  - JOUR
A1  - Manukjan, Georgi
A1  - Wiegering, Verena
A1  - Reindl, Tobias
A1  - Strauß, Gabriele
A1  - Klopocki, Eva
A1  - Schulze, Harald
A1  - Andres, Oliver
T1  - Novel variants in FERMT3 and RASGRP2 - Genetic linkage in Glanzmann-like bleeding disorders
JF  - Pediatric Blood & Cancer
N2  - Defects of platelet intracellular signaling can result in severe platelet dysfunction. Several mutations in each of the linked genes FERMT3 and RASGRP2 on chromosome 11 causing a Glanzmann‐like bleeding phenotype have been identified so far. We report on novel variants in two unrelated pediatric patients with severe bleeding diathesis—one with leukocyte adhesion deficiency type III due to a homozygous frameshift in FERMT3 and the other with homozygous variants in both, FERMT3 and RASGRP2 . We focus on the challenging genetic and functional variant assessment and aim to accentuate the risk of obtaining misleading results due to the phenomenon of genetic linkage.
KW  - bleding disorders other than hemophilia
KW  - hematology
KW  - hemostasis and thrombosis
KW  - platelet disorders
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-208129
VL  - 67
IS  - 2
ER  -